Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson’s disease
Figure 24.1 Phases of development for a surrogate marker of progression in Parkinson’s disease (PD). Biomarker discovery leads to identification of species that are most often first studied in cross-sectional…
Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson’s disease
Figure 19.1 Deep-brain stimulation selection decision-making algorithm, based on CAPSIT criteria. Reproduced with permission from Duker AP, Espay AJ. Surgical Treatment of Parkinson Disease: Past, Present, and Future. Neurol Clin…
Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson’s disease
Figure 6.1 Structure of dopamine and rotigotine. Pharmacokinetics Rotigotine has a broad spectrum of action across the D1–D5 receptors (Table 6.3) [12]. This, particularly its D1 activity, is in theory…
Management of pain and neuromuscular complications in Parkinson’s disease
Figure 16.1 Central pain pathways in Parkinson’s disease. Left: The lateral system is formed by the neospinothalamic, the neotrigeminothalamic, the cervical bundle and the beam of the dorsal horn whose…
Amantadine and antiglutamatergic drugs in the management of Parkinson’s disease
Figure 3.1 (A) Expression of different glutamate receptor subtypes, demonstrating the complexity expected in any attempt to modulate glutamatergic neurotransmission. (B) Illustration of the corticostriatal circuits, demonstrating the role of…
Lessons and challenges of trials involving ancillary therapies for the management of Parkinson’s disease
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 32 Lessons and challenges of trials involving ancillary therapies for the management of Parkinson’s disease Chris J. Hass, Elizabeth L. Stegemöller, Madeleine E. Hackney and…
Lessons and challenges of trials for other nonmotor complications of Parkinson’s disease
Figure 31.1 Therapeutic approach to the common nonmotor symptoms of Parkinson’s disease. Sialorrhea Drooling is present in 80% of patients with PD and is secondary to disturbances in swallowing the…
Controversy: midstage vs advanced-stage deep-brain stimulation in the management of Parkinson’s disease
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 29 Controversy: midstage vs advanced-stage deep-brain stimulation in the management of Parkinson’s disease Mallory L. Hacker and David Charles Introduction Parkinson’s disease (PD) is a…
